SPYRE THERAPEUTICS公司宣布,其候选药物Spy002在治疗第12周时取得了令人鼓舞的临床数据。
结果显示,接受治疗的患者中有33%达到了临床缓解的标准。同时,内镜检查评估显示,42%的患者实现了内镜下病情的显著改善。
这些中期数据为该药物的后续开发提供了积极信号。
SPYRE THERAPEUTICS公司宣布,其候选药物Spy002在治疗第12周时取得了令人鼓舞的临床数据。
结果显示,接受治疗的患者中有33%达到了临床缓解的标准。同时,内镜检查评估显示,42%的患者实现了内镜下病情的显著改善。
这些中期数据为该药物的后续开发提供了积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.